Literature DB >> 15853477

Executive dysfunction in major depressive disorder.

Charles DeBattista1.   

Abstract

Executive dysfunction is commonly seen in major depression. The types of executive deficits seen in depression include problems with planning, initiating and completing goal-directed activities. Executive dysfunction may vary as a function of the severity of depression. In addition, a subset of geriatric depression is also characterized by prominent deficits in executive functioning. The presence of executive dysfunction in depression is associated with vocational disability and possibly poorer treatment response. While few studies have examined the treatment of executive dysfunction in depression, preliminary work suggests that both pharmacologic interventions and psychosocial interventions such as problem solving therapy may be efficacious.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853477     DOI: 10.1586/14737175.5.1.79

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  12 in total

Review 1.  Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review.

Authors:  Hannah R Snyder
Journal:  Psychol Bull       Date:  2012-05-28       Impact factor: 17.737

2.  Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.

Authors:  Atilla Turgay; Lawrence Ginsberg; Elias Sarkis; Rakesh Jain; Ben Adeyi; Joseph Gao; Bryan Dirks; Thomas Babcock; Brian Scheckner; Cynthia Richards; Robert Lasser; Robert L Findling
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-12       Impact factor: 2.576

3.  Toward the Study of Trans-Disease Processes: A Novel Approach With Special Reference to the Study of Co-morbidity.

Authors:  Warren K Bickel; E Terry Mueller
Journal:  J Dual Diagn       Date:  2009-04-01

4.  Cognitive Remediation and Bias Modification Strategies in Mood and Anxiety Disorders.

Authors:  Alexandra K Gold; Rebecca E Montana; Louisa G Sylvia; Andrew A Nierenberg; Thilo Deckersbach
Journal:  Curr Behav Neurosci Rep       Date:  2016-10-06

5.  Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.

Authors:  Manisha Madhoo; Richard S E Keefe; Robert M Roth; Angelo Sambunaris; James Wu; Madhukar H Trivedi; Colleen S Anderson; Robert Lasser
Journal:  Neuropsychopharmacology       Date:  2013-12-06       Impact factor: 7.853

6.  Audiovisual emotional processing and neurocognitive functioning in patients with depression.

Authors:  Sophie Doose-Grünefeld; Simon B Eickhoff; Veronika I Müller
Journal:  Front Integr Neurosci       Date:  2015-01-30

7.  Factors influencing community case management and care hours for clients with traumatic brain injury living in the UK.

Authors:  Jo Clark-Wilson; Gordon Muir Giles; Stephanie Seymour; Ross Tasker; Doreen M Baxter; Mark Holloway
Journal:  Brain Inj       Date:  2016-04-08       Impact factor: 2.311

8.  Comprehensive Neuropsychiatric and Cognitive Characterization of Former Professional Football Players: Implications for Neurorehabilitation.

Authors:  Alex R Terpstra; Brandon P Vasquez; Brenda Colella; Maria Carmela Tartaglia; Charles H Tator; David Mikulis; Karen D Davis; Richard Wennberg; Robin E A Green
Journal:  Front Neurol       Date:  2019-08-07       Impact factor: 4.003

Review 9.  Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities.

Authors:  Roger S McIntyre; Ha T Nguyen; Joanna K Soczynska; Maria Teresa C Lourenco; Hanna O Woldeyohannes; Jakub Z Konarski
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

10.  Personally salient, emotionally negative task contexts provoke goal neglect in depression.

Authors:  Aliza Werner-Seidler; Theresa Dahm; Ann-Marie Golden; Tom Manly; Tim Dalgleish
Journal:  Psychol Med       Date:  2019-05-06       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.